To receive CME credit for this program:

1. Read the CME information and mark the checkbox confirming you have read the disclosures to download the PDF file below
2. Review the article and illustration
3. Login or register at the CME post test website (http://www.bucmetest.com)
4. Locate the course code I.ANG11OVA and take the test
   

Jointly sponsored by Boston University School of Medicine and the Angiogenesis Foundation

ACCREDITATION STATEMENT

This CME activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through Joint Sponsorship of Boston University School of Medicine and the Angiogenesis Foundation. Boston University School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

CREDIT DESIGNATION

Boston University School of Medicine designates this Internet activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity. Credit will be awarded provided this activity is used and completed according to instructions and a score of 70% or better is achieved. A certificate of credit will be issued to those who successfully complete the examination.

RELEASE AND EXPIRATION

Date of original release: April 30, 2011

Date of expiration: April 29, 2012

Estimated Time To Complete: 1.5 Hours

CME Course Code: I.ANG11OVA

TARGET AUDIENCE

Practicing oncologists in the U.S., researchers and medical students

HEALTHCARE GAP

Even with approved agents on the market, antiangiogenic therapy represents a relatively new approach to ovarian cancer management, which in turn leads to a critical need to rapidly and effectively educate physicians about the scientific and clinical rationale for treating tumor angiogenesis; pathways and mechanisms involved in tumor angiogenesis; strategies by which antiangiogenic agents are being integrated into traditional therapeutic protocols; efficacy and safety data emerging from well-designed and rigorous clinical studies of antiangiogenic therapy; and how this data can be used to improve clinical decision-making and outcomes for cancer patients.

In addition, many oncologists were trained before the era of targeted therapies, and therefore view cancer treatment primarily from the perspective of conventional chemotherapy and radiation therapy. The integration of targeted cancer therapies into conventional treatment paradigms represents a major challenge for community oncologists, who now must contend with a complex new array of drug interactions, side effects, complex treatment schedules, and sequencing of agents. Further, targeted/antiangiogenic therapies pose new challenges for imaging tumor response, as the traditional measures of tumor response (i.e., RECIST criteria), may not always apply to these agents.

PROGRAM LEARNING OBJECTIVES

At the conclusion of this educational activity, clinicians will be able to:

• Describe the role of tumor angiogenesis as both a disease mechanism and therapeutic target in ovarian cancer.
• Explain optimizing combinatorial agent treatment strategies.
• Interpret the outcome data from recent well-designed scientific and clinical studies of protocols studying new-targeted therapies.
• Integrate adverse events management into new therapy settings.
• Assess treatment options, efficacy data, and side effects with members of the cancer treatment team, as well as cancer patients and their family members.

METHOD OF PARTICIPATION

There are no fees for participating in and receiving credit for this online educational activity.  The participant should, in order, read the objectives and faculty disclosures, review the educational content, answer the multiple-choice post-test and complete the evaluation.  This program is available in PDF format accessible from the Angiogenesis Foundation's website (http://www.angio.org) in the CME section.  A print version is also available; for more information contact outreach@angio.org.  After reviewing the material, CME credits are available through the Boston University School of Medicine's website (http://www.bucmetest.com) by selecting the name of the program (registration required). Course code: I.ANG11OVA.

ACKNOWLEDGEMENT OF SUPPORT

This activity is supported by an educational grant from Genentech.

COURSE FACULTY

Susana Campos, M.D., M.P.H.

Assistant Professor of Medicine, Harvard Medical School

Dana-Farber Cancer Institute

Robert Burger, M.D., FACOG, FCAS

Associate Director for Research, Section of Gynecologic Oncology

Professor, Department of Surgical Oncology

Fox Chase Cancer Center

DISCLOSURE

Boston University School of Medicine asks all individuals involved in the development and presentation of Continuing Medical Education (CME) activities to disclose all relationships with commercial interests. This information is disclosed to CME activity participants. Boston University School of Medicine has procedures to resolve apparent conflicts of interest. In addition, faculty members are asked to disclose when any unapproved use of pharmaceuticals and devices is being discussed.

Susana Campos, M.D., M.P.H., Dana-Farber Cancer Institute

Faculty

Dr. Campos receive grant/research support from Genentech/Roche.

Robert Burger, M.D., Fox Chase Cancer Center

Faculty

Dr. Burger has been a consultant to GlaxoSmithKline and Pfizer and is on the Speaker’s Bureau for Eli Lilly. He has also been a consultant to Genentech/Roche, but has not accepted consulting fees or honoraria.

William W. Li, M.D.,

President, the Angiogenesis Foundation, Editor-in-Chief

Dr. Li has nothing to disclose with regard to commercial interests.

Vickie R. Driver, DPM, M.S., FACFAS, Associate Professor of Surgery, Boston University School of Medicine

Course Director

Dr. Driver receives grant/research support from KCI, sanofi-aventis, 3M, and Baxter. She serves on the Scientific Steering Committee for sanofi-aventis.

Jody Walker, M.S.

BUSM CME Program Manager

BUSM CME Program Manager has nothing to disclose with regard to commercial interests.

Roderick A. Smith, M.S.

Medical Writer, Program Manager, the Angiogenesis Foundation

Medical Writer, Program Manager has nothing to disclose with regard to commercial interests.

DISCUSSION OF UNLABELLED USE

This CME activity contains discussion of published and/or investigational use of: AMG 386, bevacizumab (Avastin®), BIBF 1120 (Vargatef™), cediranib (Recentin®), pazopanib (Votrient®), sorafenib (Nexavar®), and VEGF Trap (Aflibercept).

PRIVACY POLICY
The Office of Continuing Medical Education adheres to Boston University’s Conditions of Use and Policy on Computing Ethics. <http://www.bu.edu/cme/policies/privacy_policy.html>
Data gathered from participants who participate in Boston University School of Medicine’s (BUSM) Continuing Medical Education Internet-Based CME program is confidential.
Individual identifiable information is not shared with outside parties. Cumulative data may be analyzed by CME personnel, and, upon occasion, by individuals external to BUSM CME in order to determine trends.

THESE MATERIALS AND ALL OTHER MATERIALS PROVIDED IN CONJUNCTION WITH CONTINUING MEDICAL EDUCATION ACTIVITIES ARE INTENDED SOLEY FOR PURPOSES OF SUPPLEMENTING CONTINUING MEDICAL EDUCATION PROGRAMS FOR QUALIFIED HEALTH CARE PROFESSIONALS. ANYONE USING THE MATERIALS ASSUMES FULL RESPONSIBILITY AND RISK FOR THEIR APPROPRIATE USE. TRUSTEES OF BOSTON UNIVERSITY MAKE NO WARRANTIES OR REPRESENTATIONS WHATSOEVER REGARDING THE ACCURACY, COMPLETENESS, CURRENTNESS, NONINFRINGEMENT, MERCHANTABILITY, OR FITNESS FOR A PARTICULAR PURPOSE OF THE MATERIALS. IN NO EVENT WILL TRUSTEES OF BOSTON UNIVERSITY BE LIABLE TO ANYONE FOR ANY DECISION MADE OR ACTION TAKEN IN RELIANCE ON THE MATERIALS. IN NO EVENT SHOULD THE INFORMATION IN THE MATERIALS BE USED AS A SUBSTITUTE FOR PROFESSIONAL CARE.

TOPICS AND EDUCATIONAL CONTENT

Antiangiogenic therapy for advanced ovarian cancer

• Bevacizumab
• Small molecule angiogenesis inhibitors
• Other investigational treatment strategies
• Side effects
• Conclusions and future directions

SYSTEM REQUIREMENTS

This educational program is available in PDF format.  To view and print PDF files, you must have Adobe Reader installed on your computer. Most computers already have this software installed. If yours does not, you can download Adobe Reader free from the Adobe Web site: http://www.adobe.com.

If you have questions regarding certificates, please contact BUSM CME by email at cme@bu.edu or visit http://www.bu.edu/cme

For questions about this program, please contact the Angiogenesis Foundation at 617-401-2779 or outreach@angio.org.

Copyright 2011 by the Angiogenesis Foundation. All rights reserved.